Precision BioSciences announced today the activation of its first U.S. clinical trial site for the ELIMINATE‑B Phase 1 study of PBGENE‑HBV. The new site is located at Massachusetts General Hospital in Boston, Massachusetts, and is now actively recruiting patients with chronic hepatitis B.
The ELIMINATE‑B trial is an open‑label, multi‑part study designed to evaluate the safety and tolerability of PBGENE‑HBV and to define the optimal dose, number of administrations, and dosing interval needed to achieve a complete cure. The study enrolls HBeAg‑negative chronic hepatitis B patients and is currently recruiting at sites in Moldova, Hong Kong, New Zealand, and the United States.
By opening a U.S. site, Precision BioSciences expands its global enrollment footprint, increases access to a larger patient population, and moves the program closer to generating the data needed for regulatory submissions. This milestone demonstrates tangible progress in the company’s clinical development pipeline and supports its strategy to bring a curative gene‑editing therapy to market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.